Ardelyx Inc. (ARDX)
| Bid | 3.6 |
| Market Cap | 872.08M |
| Revenue (ttm) | 361.71M |
| Net Income (ttm) | -53.76M |
| EPS (ttm) | -0.23 |
| PE Ratio (ttm) | -15.85 |
| Forward PE | 30.19 |
| Analyst | Buy |
| Ask | 3.81 |
| Volume | 2,670,783 |
| Avg. Volume (20D) | 5,344,679 |
| Open | 3.68 |
| Previous Close | 3.69 |
| Day's Range | 3.62 - 3.76 |
| 52-Week Range | 3.21 - 8.06 |
| Beta | 0.59 |
About ARDX
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for ARDX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts
16 hours ago · accessnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDXNEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ:ARDX). Such investors are advise...
3 weeks ago · accessnewswire.com
ATTENTION ARDX Investors: Securities Fraud Investigation Underway - Contact Levi & KorsinskyNEW YORK, NY / ACCESS Newswire / May 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Ardelyx, Inc. ("Ardelyx, Inc.") (NASDAQ:ARDX) concerning possible violatio...
3 weeks ago · accessnewswire.com
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Ardelyx, Inc. (ARDX)NEW YORK, NY / ACCESS Newswire / May 10, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Ardelyx, Inc. ("Ardelyx, Inc.") (NASDAQ:ARDX) concerning possible violatio...
4 weeks ago · accessnewswire.com
Ardelyx, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - ARDXNEW YORK, NY / ACCESS Newswire / May 8, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Ardelyx, Inc. ("Ardelyx, Inc.") (NASDAQ:ARDX) concerning possible violation...
1 month ago · seekingalpha.com
Ardelyx: Revenue Misses And Losses Widen Amid XPHOZAH UncertaintyArdelyx's Q1 earnings reveal a sequential drop in revenue and a sharp rise in SG&A expenses, leading to a substantial operational loss. The company faces reimbursement challenges for XPHOZAH, raising ...
